Furthermore, Ibalizumab, a CD4-directed, post-attachment inhibitor, was approved by the U.S. FDA to treat HIV-1 infection and multidrug-resistant HIV-1 infection in combination with other antiretroviral(s) [22]. This evidence concerns the gene CD4 and HIV-1 infection.